Radius Health Stock News

Radius Health Inc. (NASDAQ:RDUS) price is hovering lower on Wednesday, December 08, dropping -42.58% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

The Menarini Group and Radius Health Inc (NASDAQ: RDUS ) have provided details on the elacestrant data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. As previously announced, the study met its two primary endpoints : progression-free survival (PFS) in Full story available on Benzinga.com

FLORENCE, Italy and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) provided d

FLORENCE, Italy and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The Menarini Group (Menarini) and Radius Health, Inc. (Radius) (NASDAQ: RDUS) (collectively, the Companies) provided details on the elacestrant data from the EMERALD trial following the positive results presented today at the San Antonio Breast Cancer Symposium (SABCS). The data was presented as a Late Breaker and shared in an oral presentation by Dr. Aditya Bardia, MD.

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal system (abalo-TDS) compared to abaloparatide subcutaneous injection (TYMLOS) in postmenopausal women with osteoporosis.

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below:

The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have provided details on the elacestrant data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. As previ

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.

Analysts forecast that Radius Health, Inc. (NASDAQ:RDUS) will report $63.10 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Radius Healths earnings. The highest sales estimate is $68.94 million and the lowest is $60.90 million. Radius Health posted sales of $62.78 million in the same quarter last []

In last trading session, Radius Health Inc. (NASDAQ:RDUS) saw 0.65 million shares changing hands with its beta currently measuring 1.18. Companys recent per share price level of $14.93 trading at -$1.1 or -6.86% at ring of the bell on the day assigns it a market valuation of $719.92M. That closing price of RDUSs stock is Radius Health Inc. (NASDAQ:RDUS) Drops -6.86 Percent, But More Could Be Coming. Read More »

Bank of America initiated coverage on shares of Radius Health (NASDAQ:RDUS) in a research report sent to investors on Friday, The Fly reports. The brokerage issued an underperform rating and a $16.00 price objective on the biopharmaceutical companys stock. Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group lifted []

Radius Health, Inc. (NASDAQ:RDUS) was the recipient of a large decrease in short interest in November. As of November 15th, there was short interest totalling 2,960,000 shares, a decrease of 29.0% from the October 31st total of 4,170,000 shares. Approximately 6.3% of the companys stock are sold short. Based on an average trading volume of []

Here is how Schnitzer Steel (SCHN) and South32 Ltd. (SOUHY) have performed compared to their sector so far this year.